The Latest Breaking News from Abbott

Helen Giza of FME is excited about the possibilities new drugs such as Ozempic could offer for renal patients

Abbott stock surged early Friday after a jury decided baby formula from Abbott and Mead Johnson are not responsible for a boy's disease.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Abbott is all set to release its third-quarter earnings later this month, and analysts expect a single-digit profit increase.

A global network of doctors and laboratories is working to pinpoint emerging viral threats, including many driven by climate change, in a bid to head off the world's next pandemic.

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

MedTech stocks are at the forefront of revolutionizing healthcare with the dynamic growth potential of technology. Amid this backdrop, it could be wise to consider investing in companies like Medtronic (MDT), STERIS (STE), and Hologic (HOLX), which are transforming the way healthcare is delivered and tailoring it to individual patient…

Abbott Laboratories launched its newest CGM in the U.S. on Thursday. The biosensor named Lingo is the first-ever for people without diabetes.

Discover three proven, quality companies you can own to get through a looming recession.